Diabetes and prognosis in a breast cancer cohort

Schrauder, Michael G.; Fasching, Peter A.; Häberle, Lothar; Lux, Michael P.; Rauh, Claudia; Hein, Alexander; Bayer, Christian; Heusinger, Katharina; Hartmann, Arndt; Strehl, Johanna; Wachter, David; Schulz‐Wendtland, Rüdiger; Adamietz, Boris; Beckmann, Matthias W.; Loehberg, Christian R.

doi:10.1007/s00432-010-0960-2

Cited by 59 publications

(60 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with a (17). However, in the study by Schrauder et al, the ER-negative patients with T2DM also exhibited a higher distant metastasis risk than those without T2DM.…”

supporting

confidence: 86%

Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus

Bai

Liu

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Type 2 diabetes mellitus (T2DM) can increase the risk of several common cancers, including breast cancer (BC). The purpose of the present study was to investigate the clinicopathological features and prognosis of BC patients with or without T2DM. Seventy-eight patients were diagnosed with T2DM prior to the diagnosis of BC in the Cancer Hospital of Shantou University Medical College (Shantou, China) between 2002 and 2008. A total of 300 BC patients without T2DM were randomly selected as study controls during the same period. The clinicopathological characteristics, overall survival (OS) and disease-free survival (DFS) rates of these two groups were compared. Fifty-five BC patients and 133 control patients with T2DM were >50 years old (70.5 and 44.3%, respectively). There were more T2DM BC patients with body mass index (BMI) ≥25 kg/m 2 (46.2 vs. 23.3%) and these patients had a higher rate of lymph node involvement (67.9 vs. 55.0%). The DFS of the two groups was 32.1 vs. 22.3%. The OS of the two groups was 24.4 vs. 13.7%. Following adjustment for BMI, tumor-node metastasis stage and stratification of age, the relapse risk of T2DM BC patients was >2-fold higher than that of the control group in the estrogen receptor/progesterone receptor (ER/PR)-positive patients. In Her-2-negative BC patients, the relapse risk of T2DM patients was 2.237-fold higher than that of the non-T2DM patients. In conclusion, T2DM BC patients were significantly older and more likely to be overweight, and had more lymph nodes involvement. T2DM was associated with poor prognosis in ER/PR positive or Her-2-negative BC patients.

show abstract

supporting

confidence: 86%

Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus

Bai

Liu

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Breast cancer patients with type II diabetes and ER-negative breast cancer had a more than 2-fold higher risk for distant metastasis compared to patients without diabetes, but this was not seen in patients with ER-positive tumors (31).…”

Section: Introductionmentioning

confidence: 87%

Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort

Markkula

Bromée

Henningson

et al. 2012

Cancer Causes Control

View full text Add to dashboard Cite

Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort.Markkula, Andrea; Bromée, Anna; Henningson, Maria; Hietala, Maria; Ringberg, Anita; Ingvar, Christian; Rose, Carsten; Jernström, Helena Link to publication Citation for published version (APA): Markkula, A., Bromée, A., Henningson, M., Hietala, M., Ringberg, A., Ingvar, C., ... Jernström, H. (2012). Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort. Cancer Causes and Control, 23(8), 1307-1316. DOI: 10.1007 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal

show abstract

“…Several studies have shown that pre-existing diabetes is associated with the presence of more advanced breast cancer at the time of the initial diagnosis [28,[32][33][34][35][36]. Some caution is necessary in attributing this observation to a diabetesinduced acceleration in tumor progression, because there are reports of lower participation rates of diabetic women in screening mammography for breast cancer compared with the general female population [37,38].…”

Section: Type 2 Diabetes and Breast Cancer Prognosismentioning

confidence: 97%

Type 2 Diabetes and Obesity Metabolic Interactions: Common Factors for Breast Cancer Risk and Novel Approaches to Prevention and Therapy

Vona-Davis¹,

Rose²

2012

CDR

View full text Add to dashboard Cite

The objective was to review type 2 diabetes as a risk factor for breast cancer, its influence on tumor aggressiveness and prognosis, and the interactions with obesity. Consideration was given to the responsible biological mechanisms and how these relate to the potential of hypoglycemic agents, notably metformin, as breast cancer chemotherapeutic agents. Most epidemiological studies indicate that type 2 diabetes is a modest positive risk factor for postmenopausal, but not premenopausal, breast cancer; indeed before the menopause it may be associated with a reduced risk. This pattern of differing effects on risk according to menopausal status is well established in obesity; however, although most type 2 diabetics are obese, the relationship with postmenopausal breast cancer does not appear to be a function of the body mass index. We suggest that before menopause the protective effect of obesity may modify any adverse effects of the metabolic changes related to type 2 diabetes. Regardless of menopausal status, obesity is associated with breast cancers that exhibit aggressive biological characteristics at the time of diagnosis and have a poor prognosis; a similar relationship is emerging for type 2 diabetes. The two metabolic disorders share biological mechanisms for their associations with breast cancer, including a direct effect of insulin on breast cancer cell proliferation, increased extraglandular estrogen production and bioavailability, changes in the adipokines, notably adiponectin, and activation of the AMP-activated protein kinase pathway. These mechanistic considerations are consistent with metformin having high potential as a breast cancer chemopreventive and therapeutic agent.

show abstract

Diabetes and prognosis in a breast cancer cohort

Abstract: In this study, patients with diabetes and oestrogen receptor negative breast cancer had a more than 2-fold higher risk for distant metastasis compared to patients without diabetes. Diabetes was also associated with an almost 2-fold increase in mortality within the 5 years follow-up period.

Cited by 59 publications

References 37 publications

Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus

Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus

Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort

Type 2 Diabetes and Obesity Metabolic Interactions: Common Factors for Breast Cancer Risk and Novel Approaches to Prevention and Therapy

Contact Info

Product

Resources

About